Addressing 14 modifiable risk factors, starting in childhood and continuing throughout life, could prevent or delay nearly half of dementia cases, even as people around the world live longer and the number of people with dementia is set to rise dramatically in all countries, according to the third Lancet Commission on dementia prevention, intervention, and care, which is being presented at the Alzheimer’s Association International Conference (AAIC 2024)[1].
Based on the latest available evidence, the new report adds two new risk factors that are associated with 9% of all dementia cases —with an estimated 7% of cases attributable to high low-density lipoprotein (LDL) or “bad” cholesterol in midlife from around age 40 years, and 2% of cases attributable to untreated vision loss in later life.
These new risk factors are in addition to 12 risk factors previously identified by the Lancet Commission in 2020 (lower levels of education, hearing impairment, high blood pressure, smoking, obesity, depression, physical inactivity, diabetes, excessive alcohol consumption, traumatic brain injury [TBI], air pollution and social isolation), which are linked with 40% of all dementia cases [2].
The new report estimates that the risk factors associated with the greatest proportion of people developing dementia in the global population are hearing impairment and high LDL cholesterol (7% each), along with less education in early life and social isolation in later life (5% each).
- Vision loss and high cholesterol add to 12 previously identified modifiable risk factors for dementia, concludes a new report from the 2024 Lancet Commission.
- The potential to prevent and better manage dementia is high if action to tackle these risk factors begins in childhood and continues throughout life, even in individuals with high genetic risk for dementia.
- New report outlines 13 recommendations for individuals and governments to help reduce risk, including preventing and treating hearing loss, vision loss, and depression; being cognitively active throughout life; using head protection in contact sports; reducing vascular risk factors (high cholesterol, diabetes, obesity, high blood pressure); improving air quality; and providing supportive community environments to increase social contact.
- Using England as an example, additional new research that modelled the economic impact of implementing some of these recommendations suggests that England could achieve cost savings of around £4 billion with population-level interventions that tackle dementia risk factors of excess alcohol use, brain injury, air pollution, smoking, obesity, and high blood pressure.
Addressing 14 modifiable risk factors, starting in childhood and continuing throughout life, could prevent or delay nearly half of dementia cases, even as people around the world live longer and the number of people with dementia is set to rise dramatically in all countries, according to the third Lancet Commission on dementia prevention, intervention, and care, which is being presented at the Alzheimer’s Association International Conference (AAIC 2024)[1].
Based on the latest available evidence, the new report adds two new risk factors that are associated with 9% of all dementia cases —with an estimated 7% of cases attributable to high low-density lipoprotein (LDL) or “bad” cholesterol in midlife from around age 40 years, and 2% of cases attributable to untreated vision loss in later life.
These new risk factors are in addition to 12 risk factors previously identified by the Lancet Commission in 2020 (lower levels of education, hearing impairment, high blood pressure, smoking, obesity, depression, physical inactivity, diabetes, excessive alcohol consumption, traumatic brain injury [TBI], air pollution and social isolation), which are linked with 40% of all dementia cases [2].
The new report estimates that the risk factors associated with the greatest proportion of people developing dementia in the global population are hearing impairment and high LDL cholesterol (7% each), along with less education in early life and social isolation in later life (5% each).
The Commission, authored by 27 world-leading dementia experts, calls for governments and individuals to be ambitious about tackling risks across the life course for dementia, arguing that the earlier we can address and reduce risk factor levels, the better. The report outlines a new set of policy and lifestyle changes to help prevent and better manage dementia.
More action needed worldwide to reduce dementia risks
Because of the rapidly ageing population around the world, the number of people living with dementia is expected to almost triple by 2050, rising from 57 million in 2019 to 153 million [3]. Increasing life expectancy is also driving a surge in people with dementia in low-income countries [4]. Global health and social costs related to dementia are estimated at over $1 trillion every year [5].
However, in some high-income countries, including the USA and UK, the proportion of older people with dementia has fallen, particularly among those in socio-economically advantaged areas [6]. The report authors say that this decline in people developing dementia is probably in part due to building cognitive and physical resilience over the life course and less vascular damage as a result of improvements in healthcare and lifestyle changes, demonstrating the importance of implementing prevention approaches as early as possible.
Nevertheless, most national dementia plans do not make specific recommendations about diversity, equity, or inclusion of people from underserved cultures and ethnicities who are disproportionately affected by dementia risks [7].
“Our new report reveals that there is much more that can and should be done to reduce the risk of dementia. It’s never too early or too late to take action, with opportunities to make an impact at any stage of life”, says lead author Professor Gill Livingston from University College London, UK. “We now have stronger evidence that longer exposure to risk has a greater effect and that risks act more strongly in people who are vulnerable. That’s why it is vital that we redouble preventive efforts towards those who need them most, including those in low- and middle-income countries and socio-economically disadvantaged groups. Governments must reduce risk inequalities by making healthy lifestyles as achievable as possible for everyone.”
To reduce dementia risk throughout life, the Commission outlines 13 recommendations to be adopted by governments and individuals, including (see key messages on page 2 of the report for the full list):
• Provide all children with good quality education and be cognitively active in midlife.
• Make hearing aids available for all those with hearing loss and reduce harmful noise exposure.
• Detect and treat high LDL cholesterol in midlife from around age 40 years.
• Make screening and treatment for vision impairment accessible for all.
• Treat depression effectively.
• Wear helmets and head protection in contact sports and on bikes.
• Prioritise supportive community environments and housing to increase social contact.
• Reduce exposure to air pollution through strict clean air policies.
• Expand measures to reduce smoking, such as price control, raising the minimum age of purchase, and smoking bans.
• Reduce sugar and salt content in food sold in stores and restaurants.
These actions are especially important given new evidence which shows that reducing the risks of dementia not only increases years of healthy life but also reduces the time people who develop dementia spend in ill health.
As Professor Livingston explains, “Healthy lifestyles that involve regular exercise, not smoking, cognitive activity in midlife (including outside formal education) and avoiding excess alcohol can not only lower dementia risk but may also push back dementia onset. So, if people do develop dementia, they are likely to live less years with it. This has huge quality of life implications for individuals as well as cost-saving benefits for societies.”
England could achieve cost savings of around £4 billion
In a separate study publishing in The Lancet Healthy Longevity journal alongside the Commission, Professor Livingston, lead author Naaheed Mukadam, and co-authors modelled the economic impact of implementing some of these recommendations, using England as an example. The study’s findings suggest that using population-level interventions of known effectiveness to tackle dementia risk factors of excess alcohol use (more than 21 units per week), brain injury, air pollution, smoking, obesity, and high blood pressure could achieve cost savings of more than £4 billion and over 70,000 quality-adjusted life-year (QALY) gains (one QALY equates to a year of life in perfect health). The authors stress that potential benefits may be even greater in low- and middle-income countries and any country where population-level interventions such as public smoking bans and compulsory education are not already in place.
“Given the much higher burden of dementia risk factors in low- and middle-income countries with the expected rise in dementia over the next few decades from rapid population aging and increased rates of high blood pressure, diabetes, and obesity, we need urgent policy-based preventative approaches that will have huge potential benefits far in excess of the costs”, says report co-author Dr Cleusa Ferri from Universidade Federal de Sao Paulo and Hospital Alemão Oswaldo Cruz, Sao Paulo Brazil.
Commission co-author Dr Naaheed Mukadam of University College London adds, “Prioritising population-level approaches that improve primary prevention (eg, reducing salt and sugar intake) and effective health care for conditions like obesity and high blood pressure, restricting smoking and air pollution, and enabling all children to gain a good education, could have a profound effect on dementia prevalence and inequalities, as well as significant cost savings.”
Prioritising advances in research and support for people living with dementia
The report also discusses the hopeful advances in blood biomarkers and the Anti-amyloid β antibodies for Alzheimer’s disease. The authors explain that blood biomarkers are a significant move forward for people with dementia, potentially increasing scalability and decreasing the intrusiveness and the cost of testing for accurate diagnosis. While there are promising clinical trials, the report authors caution that Anti-amyloid β antibody treatments are new, without long-term data available, and call for more research and expanded transparency about the short and long-term side effects.
Finally, the report calls for more support for people living with dementia and their families. The authors stress that in many countries, effective interventions known to benefit people with dementia are still not available or a priority, including activity interventions that provide enjoyment and reduce neuropsychiatric symptoms and cholinesterase inhibitors for slowing cognitive decline in Alzheimer’s. Similarly, many carers’ needs are unevaluated and unmet. They recommend providing multi-component coping interventions for family caregivers who are at risk of depression and anxiety, including providing emotional support, planning for the future, and information on medical and community-based resources.
The authors note that while nearly all the evidence for dementia still comes from high-income countries, there is now more evidence and interventions from LMICs, but interventions usually need to be modified to best support different cultures, beliefs, and environments. They also point out that the prevention estimates assume there is a causal relationship between risk factors and dementia, and while they were careful to only include risk factors with convincing evidence, they note that some associations may only be partly causal. For example, while unremitting depression in midlife may be causal, depression in late life may be caused by dementia. Finally, they note that this risk modification affects the population, and does not guarantee that any individual will avoid dementia.
NOTES TO EDITORS
The Lancet Commission was funded by University College London, UK, Alzheimer’s Society, Alzheimer’s Research UK and the Economic and Social Research Council. The full list of researchers and institutions who conducted the research is available in the Commission report.
The Lancet Healthy Longevity paper was funded by the NIHR Three Schools.
Quotes from Authors cannot be found in the text of the Article, but have been supplied for the press release.
[1] The Commission report will be presented during the Alzheimer’s Association International Conference (AAIC 2024) in Philadelphia, Pennsylvania on Wednesday 31 July 2024, at 4:15 p.m. ET and will be open to media and delegates attending the conference. Full program details are available here: https://aaic.alz.org/program/scientific-sessions.asp
[2]
[3] Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019 – PMC (nih.gov)
[4] The global burden of neurological disorders: translating evidence into policy – PMC (nih.gov)
[5] The worldwide costs of dementia in 2019 – Wimo – 2023 – Alzheimer’s & Dementia – Wiley Online Library
[6] Twenty-seven-year time trends in dementia incidence in Europe and the United States – PMC (nih.gov)
[7] Protection against discrimination in national dementia guideline recommendations: A systematic review | PLOS Medicine
Journal
The Lancet
Method of Research
Literature review
Subject of Research
People
Article Title
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Article Publication Date
31-Jul-2024
COI Statement
SA declares grants from the Indian Council for Medical Research
(2022–25), the Government of Karnataka (2022–23), Rotary Bangalore
Midtown (2022–23), Lowes Services India (2022–25), and Wellcome
Trust (2023–26); payment for expert testimony received by Indian
Council of Medical Research and Ashoka University; and a travel grant
paid by University College London for being part of the Lancet
Commission. SB declares grants from National Institute for Health and
Care Research (NIHR), Economic and Social Research Council,
Engineering and Physical Science Research Council, Canadian Institute
for Health Research, the Alzheimer’s Association, the Alzheimer’s
Society, Health Education England, Alzheimer’s Association,
Alzheimer’s Society, and Health Education England. He has held the
following positions: Non-Executive Director Somerset NHS Foundation
Trust, Trustee of the Alzheimer’s Society, Executive Dean of the
University of Plymouth, and Pro-Vice Chancellor of the University of
Nottingham. AB acts as a consultant for Lilly, TauRx Pharmaceuticals,
and Eisai and carries out medico–legal work for solicitors. NCF declares
consulting fees from F Hoffmann-La Roche, Eli Lilly, Ionis, Biogen, and
Siemens; participation in data safety monitoring or advisory board for
Biogen; and being a member of the Research Strategy Council for the
Alzheimer’s Society. LNG declares owning tailored activity programme
licences. MK declares grants from Wellcome Trust (221854/Z/20/Z),
the Medical Research Council (R024227), the National Institute on Aging
(R01AG062553, R01AG056477), and the Academy of Finland (350426).
KYL declared fellowship from Medical Research Council. EBL receives
grants from the National Institutes of Health (NIH) and royalties from
UpToDate. GL declares support for the manuscript from the Alzheimer’s
Society, the Alzheimer’s Society UK, and UK Research and Innovation,
who gave grants to pay for travel and accommodation. She is supported
by the University College London Hospitals’ NIHR Biomedical Research
Centre, by North Thames NIHR Applied Research Collaboration, and as
an NIHR Senior Investigator and has grants from NIHR Health
Technology Assessment, NIHR Programme Grants for Applied
Research, the Alzheimer’s Association, the Norwegian Research Council,
and Wellcome, outside of the submitted work. She works with the
Alzheimer’s Society as a member of the Research Strategy Council and
is a trustee of Nightingale Hammerson care homes. KR declares grants
from Canadian Institutes of Health Research, the Canadian Frailty
Network, and Research Nova Scotia; royalties from Biotest, Qu Biologics,
AstraZeneca UK, BioAge Labs, Congenica, Icosavax, KCR, Faraday
Pharmaceuticals, Synairgen Research, Enanta Pharmaceuticals, Pfizer,
Boehringer Ingelheim International, Fresenius Kabi Deutschland,
Baycrest Geriatric Care, and Shanghai Ark Biopharmaceutical; payment
or honoraria from University of British Columbia, Fraser Health
Authority, McMaster University, Chinese Medical Association,
Wake Forest University Medical School Centre, University of Omaha,
and Atria Institute; participation on data safety or advisory board for
EpiPharma; and leadership of the Canadian Consortium on
Neurodegeneration in Dementia, Cap Breton University, and Nova
Scotia Health. KS declares support from the Japan Society for the
Promotion of Science fund (22H03352, 21KK0168, 16KK0059).
LSS declares support from Della Martin Foundation, the NIH (P30
AG066530, R01 AG051346, R01 AG062687, R01 AG051346, R01
AG055444, P01 AG052350, R01 AG053267, R01 AG074983, R01
AG063826), Abbott, Biohaven, Biogen, Eisai, and Eli Lilly and consulting
fees from AC Immune, Cortexyme, Alpha-cognition, BioVie, Athira, Eli
Lilly/Avid, Corium, Lundbeck, Merck, Muna Therapeutics,
Novo-Nordisk, Neurim, NeuroDiagnostics, Ono, Otsuka, Roche/
Genentech, Cognition, Lighthouse, GW Research, ImmunoBrain, and
Bristol Myers Squibb. AS declares grants from Wellcome Trust, the
Alzheimer’s Association, Brain Canada, and the NIHR. YY declares
support from the National Natural Science Foundation of China
(72374013) and the National Key R&D Program of China
(2023YFB4603200, 2023YFC3606400). SW declares an NIHR doctoral
training fellowship. GS has participated on advisory boards for the
following pharmaceutical companies manufacturing drugs against
Alzheimer’s disease: Biogen, Roche, and Eisai. LG is an inventor of a
training program for health and human service professionals in an
evidence-based tailored activity intervention, the Tailored Activity
Program; she and her respective universities are entitled to fees. All
other authors declare no competing interests
Discover more from Science
Subscribe to get the latest posts sent to your email.